Be Bio’s haemophilia B treatment gains FDA orphan drug status
The US FDA has granted orphan drug designation to Be Biopharma’s (Be Bio) BE-101 for the treatment of haemophilia B.
The US FDA has granted orphan drug designation to Be Biopharma’s (Be Bio) BE-101 for the treatment of haemophilia B.
What's Your Reaction?
